Market capitalization | $85.73b |
Enterprise Value | $90.89b |
P/E (TTM) P/E ratio | 37.05 |
EV/FCF (TTM) EV/FCF | 43.22 |
EV/Sales (TTM) EV/Sales | 10.20 |
P/S ratio (TTM) P/S ratio | 9.62 |
P/B ratio (TTM) P/B ratio | 17.29 |
Dividend yield | 0.82% |
Last dividend (FY23) | $1.56 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
20 Analysts have issued a Zoetis, Inc. Class A forecast:
20 Analysts have issued a Zoetis, Inc. Class A forecast:
Jun '24 |
+/-
%
|
||
Revenue | 8,915 8,915 |
8%
8%
|
|
Gross Profit | 6,091 6,091 |
8%
8%
|
|
EBITDA | 3,717 3,717 |
8%
8%
|
EBIT (Operating Income) EBIT | 3,214 3,214 |
8%
8%
|
Net Profit | 2,344 2,344 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zoetis, Inc. discovers, develops and manufactures a portfolio of animal health medicines and vaccines. The company operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The company provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals. Zoetis was founded in 1952 and is headquartered in Parsippany, NJ.
Head office | United States |
CEO | Kristin Peck |
Employees | 14,100 |
Founded | 1952 |
Website | www.zoetis.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.